Doing Less Can Be Doing More for Healthcare – the Biggest Takeaway From ASCO 2018
Health Populi
JUNE 5, 2018
The conclusion of the paper states, “Adjuvant endocrine therapy and chemoendocrine therapy had similar efficacy in women with hormone-receptor-positive, HER2-negative, axillary node-negative breast cancer who had a midrange 21-gene recurrence score.” The second chart illustrates patient-borne costs for early stage breast cancer.
217 
Let's personalize your content